Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

David received his MB PhD qualification from of Guy’s and St Thomas’ Medical School London. He undertook an intercalated PhD studying the role of neurotrophic factors in sensory neuronal development and the generation of persistent pain. Sub-speciality training in neurology took place principally in London at the National Hospital for Neurology and Neurosurgery, King’s College Hospital and Guy’s and St Thomas’ NHS Trust.

Click here for Dr Bennett's profile page

He developed a sub-specialty interest in peripheral neuropathy as well as neuropathic pain having trained with Profs Richard Hughes, Mary Reilly and Dr John Scadding; After completion of training he was appointed consultant neurologist at King’s College Hospital and Guy’s and St Thomas’ NHS Trust. He received an intermediate Wellcome Clinical Scientist fellowship based at King’s College London in 2006 and subsequently obtained a Senior Fellowship. He is a member of the Wellcome Trust funded London Pain Consortium and is vice-director of the ‘Europain’ Investigational Medicines Initiative.

His research interest is to understand the pathogenesis of nerve injury in order to promote nerve repair and prevent the development of neuropathic pain. He takes a broad experimental approach to this problem ranging from the study of transgenic mouse models to the investigation of rare inherited neuropathies and painful channelopathies.

WHAT STARTED YOUR INTEREST IN NEUROSCIENCE?

I intercalated a BSc in neuroscience which sparked my interest in this field. I then received a Wellcome Trust summer vacation scholarship to work with Pat Wall and Steve McMahon at St Thomas’ who taught me many practical skills but more importantly how to approach science with enthusiasm and imagination. At the end of the summer I spent a month visiting Genentech, San Francisco studying neurotrophic factors at a time when new ligands and receptors were being cloned on an almost weekly basis. At this point I was certain I wanted to study how these important signalling molecules may have a role in sensory neuronal survival and plasticity. Upon my return I received a scholarship to undertake an intercalated PhD and I was hooked on neuroscience.  

WHAT DO YOU SEE AS THE BIGGEST CHALLENGE IN NEUROSCIENCE OVER THE NEXT 5-10 YEARS?

We now have some amazing technology platforms to study the nervous system whether at the level of gene expression in individual neurons to brain imaging. It is a significant challenge to combine datasets across such disparate technologies in order to understand the integrated function of the nervous system. What makes pain biology so interesting is that advance will only be made by using such a multidisciplinary approach. On a practical level the knowledge of the molecular events mediating somatosensation has increased exponentially over the last two decades we now need to focus on turning this new knowledge into patient benefit.  

WHAT DO YOU CONSIDER YOUR GREATEST ACHIEVEMENT?

Dating back to my PhD and post-doctoral work I demonstrated that nerve growth factor modulates the sensitivity of sensory neurons in adulthood and is an important inflammatory pain mediator. This has led to the development of humanised monoclonals to NGF by a number of companies which have since shown efficacy in phase III clinical trials. It has been interesting to see the drug development process in action although there is still some way to go prior to such drugs being licensed.

Similar stories

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.